Thursday, November 19, 2009

German biotech Caprotec opens Burlington subsidiary

By Mass High Tech staff

Video Gallery

MHT's Julie Donnelly: Life science startups finding investments

MHT's Marc Songini: Technology to keep seniors healthy

MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban

Related News

Ischemix moves prevention drug to Phase 2a trials [March 10, 2010]

Talaris Advisors names Lee as financial and development officer [March 9, 2010]

Biogen, Roche halt arthritis drug trial [March 9, 2010]

Interleukin to net $5M from securities offering [March 5, 2010]

NanoViricides to raise $40M through occasional stock sales [March 5, 2010]

Caprotec bioanalytics GmbH, a Berlin biotechnology firm, has opened a subsidiary in Burlington. Called caprotec Inc., the subsidiary will cover North American sales, support and marketing for its Capture Compound Mass Spectrometry (CCMS) technology.

Caprotec’s CCMS technology, used in proteomics research, focuses on small molecules that capture and isolate proteins based on functionality.

The company announced, as part of the new subsidiary, Christian Jurinke, a biotech veteran most recently of San Diego-based Sequenom Inc., would take over as president of the U.S. subsidiary. Genovative Solutions LLC, a biotech research tools firm with which caprotec has partnered for sales and marketing, has brought in its founder Jeff Protentis as the Burlington subsidiary’s lead agent in North America.

Other biotech-focused spectrometry companies include Woburn-based biotech BioTrove Inc., which last week announced plans to be acquired by Carlsbad, Calif.-based Life Technologies Corp.  and Waters Corp. of Milford, which announced in April plans to establish a center at the University of Warwick in England focused on biomedical mass spectrometry research.